THE TEAM.
NOVAPEP IS DRIVEN BY A WORLD-CLASS TEAM OF SCIENTISTS AND INDUSTRY LEADERS ADVANCING PEPTIDE-BASED THERAPEUTICS.
SCIENTIFIC ADVISORY BOARD.
-
Professor, Dept of Translational Medicine, Scripps Research.
-
NMR studies of peptide/protein structures at the French AEC Laboratory.
-
Published over 200 papers in Activated Protein C and APC mutants.
-
Inventor of TR47 - the PAR1 agonist peptide.
-
Co-inventor of NVP-202 - the PAR1-PAR3 agonist peptide structure.
Prof Phil Dawson
AB, PhD
-
Professor, Department of Chemistry, Scripps Research.
-
Dean Emeritus of Graduate and Postdoctoral Studies, Skaggs Graduate School of Chemical and Biological Science, Scripps Research.
-
Development of Methods to Incorporate Unnatural Chemical Groups into Proteins.
-
Chairman of the Peptide Therapeutics Foundation.
Prof Silvio Danese
MD, PhD
-
Silvio Danese is a Gastroenterologist and Professor of Gastroenterology at San Raffaele University and San Raffaele Hospital, Milan, where he is Head Gastroenterology.
-
He is involved in many international clinical trials in IBD and has published more than 700 papers in journals, including NEJM and Lancet.
-
He is Past President European Crohn´s and Colitis Organization (ECCO).
-
He has published papers on APC in IBD.
Prof Yugeesh Lankadeva
BBMed. MBA, PhD
-
Professor Yugeesh Lankadeva leads the Translational Cardiovascular and Renal Research Group at The Florey.
-
Research on the pathophysiology of brain and kidney injury from sepsis.
-
His discoveries have translated to 10 clinical trials in Europe, US and Asia.
-
Study Director and Test Facility Manager of Florey’s GLP-accredited large animal facility, CREDOS-Biotech.
MANAGEMENT TEAM.
Rob Antulov
BE (Hons), MBA
Chairman
-
Rob is Managing Partner of Jacanda Capital and Modus Partners.
-
Previously Director of Strategy at Fairfax Media.
-
Previously was a strategy consultant with Booz & Co.
-
He has extensive Board experience of over 20 years with medical research, arts and social enterprise for-purpose organisations.
Jay Hennock
BEc
CEO & Executive Director
-
25 years in corporate advisory services with Citibank and Bank of America.
-
Co-founded Access Systems, sold to International Gaming Technology Inc.
-
Co-founded and was CFO of Nuon Therapeutics Inc.
-
Founder and CEO of Bioatrix Pty Ltd, which was sold to ZZ Biotech LLC, and he is a Director of Prokardia and Kardiomics.
Meagan Walsh
BSc (Hons), PhD
Executive Director
-
Former Novartis Regional Medical Director, AsiaPac, MEA & Africa.
-
Novartis Chief Scientific Officer, Singapore and Asian Emerging Markets.
-
Franchise Medical Head - Immunology, Hepatology and Dermatology.
-
Post Doctoral Research Associate - Newcastle University.
-
Post Doctoral Research Officer - Queensland Institute of Medical Research.
Kent Pryor
BA, MBA, PhD
Executive Director
-
Kent Pryor is a Director and Chief Executive Officer of ZZ Biotech.
-
Previously, he served as Chief Operating Officer of SynthRx, Inc., Associate Director of Drug Development at Kémia, Inc., and Group Leader at Corvas International, Inc.
-
Dr Pryor received his BA in chemistry magna cum laude from Rice University, a PhD in organic chemistry from the Massachusetts Institute of Technology, and an MBA from the Rady School of Management at the University of California, San Diego.